PT2868315T - Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos - Google Patents
Formulações melhoradas e métodos para liofilização e liofilizados assim produzidosInfo
- Publication number
- PT2868315T PT2868315T PT141883348T PT14188334T PT2868315T PT 2868315 T PT2868315 T PT 2868315T PT 141883348 T PT141883348 T PT 141883348T PT 14188334 T PT14188334 T PT 14188334T PT 2868315 T PT2868315 T PT 2868315T
- Authority
- PT
- Portugal
- Prior art keywords
- lyophilization
- produced
- methods
- improved formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99224107P | 2007-12-04 | 2007-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2868315T true PT2868315T (pt) | 2017-09-04 |
Family
ID=40718143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT141883348T PT2868315T (pt) | 2007-12-04 | 2008-12-03 | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8277845B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2224913B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP5812318B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101932308B (cg-RX-API-DMAC7.html) |
| CA (3) | CA3123813C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1119256T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2868315T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2638977T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20171223T1 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2868315T (cg-RX-API-DMAC7.html) |
| PL (1) | PL2868315T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2868315T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2868315T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009073711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2868315T1 (sl) | 2007-12-04 | 2017-10-30 | Biogen Chesapeake Llc | Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to |
| WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| WO2013086292A1 (en) * | 2011-12-09 | 2013-06-13 | Enject, Inc. | Glucagon formulations |
| MX363473B (es) | 2012-05-08 | 2019-03-25 | Aeromics Inc | Uso de fenilbenzamidas para tratar condiciones mediadas por acuaporina. |
| WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| HK1224228A1 (zh) | 2013-11-06 | 2017-08-18 | Aeromics, Inc. | 新型制剂 |
| EP3113722A4 (en) * | 2014-03-07 | 2017-12-06 | Endologix, Inc. | Forming hydrogels and materials therefor |
| TW201613888A (en) | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
| EP3302514B1 (en) | 2015-05-29 | 2022-07-06 | University of Maryland, Baltimore | Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells |
| KR102681027B1 (ko) | 2015-10-07 | 2024-07-02 | 레메디 파마슈티칼즈, 인크. | Cns 부종과 관련한 손상 또는 병태의 치료 방법 |
| US20170320862A1 (en) * | 2016-05-03 | 2017-11-09 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
| JP7165648B2 (ja) | 2016-07-29 | 2022-11-04 | バイオジェン チェサピーク エルエルシー | Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法 |
| CN108210501B (zh) | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
| KR102336425B1 (ko) | 2017-06-30 | 2021-12-07 | 무라다기카이가부시끼가이샤 | 반송 시스템 및 반송 방법 |
| CN108553428A (zh) * | 2018-05-29 | 2018-09-21 | 昆药集团股份有限公司 | 格列本脲制剂及其制备方法 |
| US20220280537A1 (en) * | 2021-03-04 | 2022-09-08 | Biogen Chesapeake Llc | Low-sorbing glyburide formulation and methods |
| WO2022195112A1 (en) | 2021-03-19 | 2022-09-22 | Eligo Bioscience | Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating acneiform rash |
| CN113274361B (zh) * | 2021-06-08 | 2022-05-06 | 吉林津升制药有限公司 | 一种烟酰胺冻干粉针剂及其制备方法 |
| CN119173250A (zh) * | 2022-03-03 | 2024-12-20 | 瑞迪制药有限公司 | 低吸附格列本脲试剂盒、制剂和方法 |
| US12251389B1 (en) | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
| DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
| US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
| GB9003185D0 (en) * | 1990-02-13 | 1990-04-11 | Ici Plc | Pharmaceutical compositions |
| WO1993013752A1 (en) | 1992-01-21 | 1993-07-22 | Sri International | Improved process for preparing micronized polypeptide drugs |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| US5977109A (en) | 1994-04-25 | 1999-11-02 | Kyowa Hakko Kogyo Co., Ltd. | Method for stabilizing compound DX-52-1 and lyophilized composition thereof |
| US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| PL193447B1 (pl) * | 1996-12-24 | 2007-02-28 | Biogen Idec Inc | Kompozycja interferonu, kompozycja farmaceutycznainterferonu oraz sposób stabilizowania kompozycjiinterferonu |
| US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| WO1999006024A1 (en) | 1997-07-29 | 1999-02-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| EP1082132A1 (en) * | 1998-05-29 | 2001-03-14 | Biogen, Inc. | Recombinant human interferon beta-1a (ifn-beta-1a) formulation |
| US6552082B2 (en) | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
| JP3956654B2 (ja) | 2000-06-29 | 2007-08-08 | 小野薬品工業株式会社 | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 |
| US20030175349A1 (en) | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| WO2002079778A2 (en) | 2001-03-28 | 2002-10-10 | Rheologics, Inc. | In vivo delivery methods and compositions |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| US20030125338A1 (en) | 2001-06-12 | 2003-07-03 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
| DK1408966T3 (da) * | 2001-07-17 | 2008-06-16 | N Gene Res Lab Inc | Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| AU2003222020B2 (en) | 2002-03-20 | 2008-08-28 | University Of Maryland Baltimore | A non-selective cation channel in neural cells and methods for treating brain swelling |
| DE10325989A1 (de) | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| DE10341414A1 (de) * | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
| NZ551128A (en) | 2004-05-20 | 2010-03-26 | Diamedica Inc | Use of hepatic parasympathetic tone modulator and diabetes drug combinations for treating insulin resistance |
| JP5085326B2 (ja) | 2004-09-18 | 2012-11-28 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法 |
| WO2006087232A1 (en) | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
| US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
| PL2071917T3 (pl) | 2006-09-29 | 2013-04-30 | Infa Sa | System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego |
| SI2868315T1 (sl) * | 2007-12-04 | 2017-10-30 | Biogen Chesapeake Llc | Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to |
-
2008
- 2008-12-03 SI SI200831850T patent/SI2868315T1/sl unknown
- 2008-12-03 LT LTEP14188334.8T patent/LT2868315T/lt unknown
- 2008-12-03 PT PT141883348T patent/PT2868315T/pt unknown
- 2008-12-03 CA CA3123813A patent/CA3123813C/en active Active
- 2008-12-03 CA CA2707484A patent/CA2707484C/en active Active
- 2008-12-03 CA CA3240562A patent/CA3240562A1/en active Pending
- 2008-12-03 PL PL14188334T patent/PL2868315T3/pl unknown
- 2008-12-03 US US12/746,164 patent/US8277845B2/en active Active
- 2008-12-03 EP EP08857974.3A patent/EP2224913B1/en active Active
- 2008-12-03 CN CN200880126038.6A patent/CN101932308B/zh active Active
- 2008-12-03 ES ES14188334.8T patent/ES2638977T3/es active Active
- 2008-12-03 WO PCT/US2008/085384 patent/WO2009073711A1/en not_active Ceased
- 2008-12-03 JP JP2010537028A patent/JP5812318B2/ja active Active
- 2008-12-03 EP EP14188334.8A patent/EP2868315B1/en active Active
- 2008-12-03 DK DK14188334.8T patent/DK2868315T3/en active
-
2012
- 2012-09-11 US US13/610,335 patent/US8858997B2/en active Active
-
2014
- 2014-10-07 US US14/508,488 patent/US10117834B2/en active Active
-
2015
- 2015-01-26 JP JP2015012350A patent/JP6084639B2/ja active Active
-
2017
- 2017-01-23 JP JP2017009474A patent/JP6377189B2/ja active Active
- 2017-08-09 HR HRP20171223TT patent/HRP20171223T1/hr unknown
- 2017-08-29 CY CY20171100905T patent/CY1119256T1/el unknown
-
2018
- 2018-07-23 JP JP2018137703A patent/JP6603762B2/ja active Active
- 2018-09-21 US US16/138,173 patent/US10426729B2/en active Active
-
2019
- 2019-08-26 JP JP2019153477A patent/JP6866438B2/ja active Active
- 2019-09-27 US US16/585,255 patent/US10869835B2/en active Active
-
2020
- 2020-12-18 US US17/126,993 patent/US20210244669A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2868315T (pt) | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos | |
| PT2144998T (pt) | Métodos e composições para vírus vivos atenuados | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0913707A2 (pt) | "artigo e métodos para preparação do artigo" | |
| BRPI0909780A2 (pt) | Composições e métodos para liberação de fármaco | |
| BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| BRPI0908379A2 (pt) | sistemas e métodos para obter dentaduras customizadas | |
| BRPI0919466A2 (pt) | composição farmacêutica para liberação modificada | |
| PT2427212T (pt) | Anticorpos anti-cd100 e métodos para utilização dos mesmos | |
| BRPI0815407A2 (pt) | Composições e métodos para controlar nematódeos | |
| BRPI0820980A2 (pt) | Composições e métodos para detecção de tiabs | |
| BRPI0814594A2 (pt) | Composições e métodos adjuvantes de antígeno | |
| DK2068886T3 (da) | Lipidholdige præparater | |
| BRPI0812562A2 (pt) | composições terapêuticas anti-cd20 e métodos | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| PT2356462T (pt) | Composições e métodos anti-cxcr1 | |
| ES2397671T8 (es) | Procedimiento para preparar voriconazol | |
| CR10571A (es) | Vacuna virica recombinante | |
| BRPI0915481A2 (pt) | material e método para produzir o mesmo | |
| BRPI0814188A2 (pt) | Formulações | |
| BRPI0821858A2 (pt) | Composto, composição para cuidado oral, e, método | |
| DK2114993T3 (da) | Vaccine | |
| BRPI0921959A2 (pt) | métodos e composições para remoção de tatuagem | |
| BRPI0822349A2 (pt) | composições e métodos para tratar doenças lisossômicas |